Observation on clinical effect of modified Sangbaipi Decoction in treating patients with acute exacerbation of chronic obstructive pulmonary disease of phlegm-heat obstructing lung type
Objective To evaluate the impact of the modified Sangbaipi Decoction on patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) of the phlegm-heat-obstructing-lung type. Methods 160 patients with AECOPD of the phlegm-heat-obstructing-lung type were randomly assigned to an observation group and a control group,with 80 cases in each group. The control group was treated with conventional symptomatic treatment such as expectorant,relieving asthma and anti-infection,and the observation group was treated with modified Sangbaipi Decoction on the basis of the control group. The traditional Chinese medicine syndrome score,lung function index,arterial blood gas index,airway inflammation index and adverse reaction occurrence were compared between the two groups. Results After treatment,the wheezing score of the observation group was (0.89±0.18) points,the chest tightness score was (0.94±0.16) points,the yellow phlegm coughing score was (0.67±0.14) points and the gurgling with sputum score was (0.73±0.15) points,which were lower than (1.61±0.25),(1.61±0.27),(1.32±0.24) and (1.27±0.22) points of the control group (P<0.05). After treatment,the observation group had dynamic lung compliance (Cdyn) of (24.39±2.55) L/kPa,peak expiratory flow rate (PEF) of (3.52±0.58) L/s,forced vital capacity (FVC) of (2.87±0.63) L,and forced expiratory volume in one second (FEV1) of (2.28±0.43) L,which were higher than (15.75±1.81) L/kPa,(2.66±0.50) L/s,(2.40±0.73) L,and (1.67±0.46) L in the control group (P<0.05). After treatment,in the observation group,the arterial partial pressure of oxygen (PaO2) was (84.11±5.64) mm Hg (1 mm Hg=0.133 kPa) and the arterial oxygen saturation (SaO2) was (93.04±2.24)％,which were higher than (72.03±4.29) mm Hg and (89.36±1.83)％ in the control group;the observation group had lower arterial partial pressure of carbon dioxide (PaCO2) of (38.41±2.84) mm Hg than (44.34±3.28) mm Hg in the control group (P<0.05). After treatment,the observation group had interleukin-17A of(12.64±4.29) pg/ml,IL-1β of (2.03±0.52) pg/ml,tumor necrosis factor like weak inducer of apoptosis (TWEAK) of (0.51±0.06) pg/ml,and procalcitonin (PCT) of (0.30±0.03) μg/L,which were lower than (24.08±5.01) pg/ml,(5.31±0.77) pg/ml,(0.63±0.10) pg/ml,and (0.75±0.06) μg/L in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group (6.25％) and control group (7.50％) (P>0.05). Conclusion Modified Sangbaipi Decoction has a good therapeutic effect and high safety on patients with AECOPD of phlegm-heat obstructing lung type,and has clinical promotion value.
万方数据
维普
